[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 20, Issue 1 (1-2022) ::
Int J Radiat Res 2022, 20(1): 61-65 Back to browse issues page
Clinical efficacy and safety of docetaxel in combination with cisplatin on the platin-sensitive recurrent ovarian cancer in comparison of whole abdominal radiotherapy
F.L. Zhang
Department of Pharmacy, the Second Affiliated Hospital of Dalian Medical University´╝îDalian, Liaoning116023, China , correspond.Zhang@yahoo.com
Abstract:   (687 Views)
Background: To investigate the clinical efficacy and safety of docetaxel in combination with cisplatin in comparison of standard methods of in treatment of platin-sensitive ovarian cancer regimens and in addition to radiotherapy for whole abdomen radiotherapy in platin-sensitive recurrent ovarian cancer and the effect on the levels of VEGF and MMP-2. Materials and Methods: We recruited a total of 160 platin-sensitive recurrent ovarian cancer patients between April 2017 and April 2020 who were treated in this hospital, and assessed them based on the treatment chemotherapy and radiotherapy regimens to control, the docetaxel+cisplatin, and Whole abdomen radiotherapy groups. Patients in the control group received the co-medication of paclitaxel and carboplatin, while those in the docetaxel+cisplatin group received the docetaxel in combination with cisplatin. Following treatment, we compared the clinical efficacy, levels of vascular endothelial growth factor (VEGF) and MMP-2 and safety of these three methods between two groups. Results: the total effectiveness rate of the docetaxel+cisplatin group was 69.09%, significantly higher than 16.36% in the control group and 24% in WAR group (P<0.05). Besides, it was found that treatment in the docetaxel+cisplatin group decreased the levels of VEGF and MMP-2 in serum of patients more evidently than those in the control and whole abdomen radiotherapy groups (P<0.05). Conclusion: docetaxel in combination with cisplatin performs well, with significant decreases in the levels of VEGF and MMP-2 and reliable safety; while there was a high rate of adverse reactions in patients undergoing whole abdomen radiotherapy.
 
Keywords: Ovarian cancer, VEGF, MMP-2, docetaxel, paclitaxel, abdomen radiotherapy.
Full-Text [PDF 1410 kb]   (518 Downloads)    
Type of Study: Original Research | Subject: Radiobiology
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zhang F. Clinical efficacy and safety of docetaxel in combination with cisplatin on the platin-sensitive recurrent ovarian cancer in comparison of whole abdominal radiotherapy. Int J Radiat Res. 2022; 20 (1) :61-65
URL: http://ijrr.com/article-1-4069-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 20, Issue 1 (1-2022) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.04 seconds with 32 queries by YEKTAWEB 4410